You can now see all the trending news of 𝕏 right on your homescreen. Add the 𝕏 News widget to your phone. Stay up to date with breaking news, big conversations, and viral moments as they happen around the world.

Today, @lifebiosciences confirmed the first patient has been dosed with an epigenetic restoration drug candidate. An exciting milestone 🚀 Life Biosciences is the OG cellular rejuvenation using epigenetic restoration to reverse diseases of aging. It was cofounded by @davidasinclair, who serves as Chairman The company’s proprietary Epigenetic Restoration platform utilizes three transcription factors, OCT4, SOX2, and KLF4 (OSK), to restore older and damaged cells to a younger and healthier state. This innovative approach targets a root cause of aging at the epigenetic level, and has the potential to address a wide range of serious age-related diseases The Phase 1 trial will evaluate the safety and tolerability of ER-100, with additional endpoints assessing visual function. ER‑100 is the first clinical candidate from Life Bio’s Epigenetic Restoration platform, which uses controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK) to restore cellular function by resetting the epigenetic code to more youthful patterns of gene expression “This is an important moment for Life Bio and for the field of aging biology,” said David Sinclair, Ph.D., Co‑founder of Life Biosciences and Professor of Genetics at Harvard Medical School. “Our research has suggested that aging is driven in large part by the loss of epigenetic information, not irreversible damage. This clinical study represents the first opportunity to test whether restoring that information can ameliorate human disease.” Beyond ER-100, the company is strategically broadening its therapeutic pipeline to address additional age-related diseases, underscoring the platform’s versatility and transformative potential. “This milestone reflects years of rigorous scientific development and translational research,” said Sharon Rosenzweig‑Lipson, Ph.D., Chief Scientific Officer of Life Biosciences. “Our preclinical studies have demonstrated that controlled OSK expression can reset epigenetic patterns associated with healthy cellular function, improve tissue performance, and restore visual function in animal models. Advancing ER‑100 into the clinic is an important step toward translating epigenetic restoration into a new class of medicines for age-related diseases.” Optic neuropathies represent a large unmet medical need. Current treatments primarily address risk factors, such as intraocular pressure in glaucoma, but do not directly target the damage to retinal ganglion cells. As a consequence, the disease often leads to irreversible vision loss despite treatment Vision loss not only directly impacts patients’ lives, but also increases the risk of loss of independence, damaging falls, and depression and dementia due to social isolation, underscoring the need for disease-modifying therapies. Beyond ER‑100, Life Bio is developing applications of its proprietary Epigenetic Restoration platform for multiple indications in a variety of organs, reflecting the broad therapeutic potential of this platform. About Optic Neuropathies Optic neuropathies are a group of disorders characterized by damage to retinal ganglion cells (RGCs), the primary neurons connecting the eye to the brain. Because RGCs do not naturally regenerate, damage results in permanent vision impairment. One such optic neuropathy, open-angle glaucoma (OAG) is a chronic neurodegenerative disease and a leading cause of blindness in older adults While often associated with elevated intraocular pressure, disease progression frequently continues despite treatment, and some patients suffer from OAG despite normal intraocular pressure. Non-arteritic anterior ischemic optic neuropathy (NAION) is the most common acute optic neuropathy in adults over fifty. It involves sudden, painless vision loss due to insufficient blood flow, for which there are currently no approved treatments About ER-100 ER‑100 is an investigational therapy in clinical development for the treatment of optic neuropathies including OAG and NAION. ER‑100 is designed to restore function in retinal ganglion cells using Life Biosciences’ Epigenetic Restoration platform, which utilizes controlled expression of three transcription factors, OCT4, SOX2 and KLF4 (OSK), to reset cellular gene expression patterns and restore cells to a more youthful and functional state. ER‑100 is currently being evaluated in a Phase 1 clinical trial. More information can be found at clinicaltrials.gov (NCT07290244): clinicaltrials.gov/study/NCT… For more information, visit lifebiosciences.com or follow on social media lifebiosciences.com/life-bio…

Tesla AI chip design engineering reviews are so great! Team is awesome. Our AI6 chip might set a record for most amount of usable intelligence from a wafer when factoring in yield.

Europe cannot promise solidarity while arming Ankara. 👇 A strategic file in @ekathimerini. Ankara does not move alone. Before Turkey coerces, Europe equips it. Before the ship sails, the drone flies, the submarine dives or the aircraft climbs, a European capital has signed. That is the contradiction Brussels refuses to name. Athens and Nicosia are told that Turkish pressure is “bilateral”, while European governments license the platforms, sustain the systems, certify the access and launder Ankara’s coercion through industry. It is not bilateral when the threatened border is European. It is not frozen when Cyprus remains occupied, Turkish forces remain in the north, Ankara militarizes the island and still refuses to recognize the Republic of Cyprus. It is not commerce when a state keeps a casus belli against Greece and turns Blue Homeland into doctrine, law and pressure. The sharper test is export law. Under Common Position 2008/944/CFSP, clear risk of aggression, force-backed claims or danger to member-state security is enough. Law must stop the license before Ankara creates the evidence. Madrid cannot architect and sustain TCG Anadolu, then call it neutral when a Spain-enabled platform parades off occupied Cyprus on the invasion’s 50th anniversary. Berlin cannot preach restraint while Turkish submarines reshape the underwater balance of the Aegean and Eastern Mediterranean. Rome cannot open Europe’s unmanned-systems gate to Baykar and hide behind industry. London sits outside the EU legal contradiction and inside NATO’s strategic one. It cannot lead Ankara up the next air-power ladder and pretend alliance language sanitizes coercion. Paris was the exception. Now it is the warning. It read the Eastern Mediterranean earlier than most, strengthened Athens and understood that Ankara was not a difficult ally, but a power problem. That is precisely why the Safran-Baykar threshold matters. Sensors, optronics, navigation and guidance are not accessories. They are the kill chain. This is Europe’s test. Article 42(7) cannot be a fire alarm after aggression while export law becomes the paperwork before it. Solidarity that begins only after the first shot is not strategy. It is condolence with a legal citation. Ankara is not a normal defense customer until it removes the casus belli, ends maritime coercion, stops using occupied northern Cyprus as a military platform and accepts the legal personality of the Republic of Cyprus. Until then, Turkish-linked defense cannot be treated as European business. No export is innocent. No sustainment is technical. No co-production is neutral. No invoice is private. Europe now runs two policies: One calls Greek and Cypriot borders European. The other arms the power designed to test them. 🔗 ekathimerini.com/opinion/130…